Startup | August 13, 2024
HealthCRED secures US$ 1.2 million in seed funding
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Report highlights significant improvements in adolescent well-being in India
Campaign launched to spread awareness regarding dengue prevention and control
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Subscribe To Our Newsletter & Stay Updated
